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ABSTRACT In young women, the use of snus increases in parallel with decreasing smoking rates but the
use in pregnancy is unclear. Our aims were to determine the prevalence of snus use, smoking and other
nicotine-containing product use during pregnancy, and to identify predictors for snus use in pregnancy.
Prevalence was determined for 2528 women in Norway and Sweden based on the Preventing Atopic
Dermatitis and ALLergies (PreventADALL) study, a population-based, mother–child birth cohort.
Electronic questionnaires were completed in pregnancy week 18 and/or week 34, and potential predictors
of snus use were analysed using logistic regression models.
Ever use of any snus, tobacco or nicotine-containing products was reported by 35.7% of women, with
similar rates of snus use (22.5%) and smoking (22.6%). Overall, 11.3% of women reported any use of
nicotine-containing products in pregnancy up to 34 weeks, most often snus alone (6.5%). Most women
(87.2%) stopped using snus by week 6 of pregnancy.
Snus use in pregnancy was inversely associated with age and positively associated with urban living and
personal or maternal history of smoking. While 11.3% of women used snus or other nicotine-containing
products at some time, most stopped when recognising their pregnancy. Younger, urban living, previously
smoking women were more likely to use snus in pregnancy.
@ERSpublications
Of the 11.3% of women using any nicotine products in pregnancy (most often snus (6.5%)), the
majority stop within pregnancy week 6. Snus use is associated with urban living, previous
smoking, in utero smoking exposure of the index woman and lower age. http://ow.ly/Gyg230nmxIo
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ORIGINAL ARTICLE
NICOTINE AND PREGNANCY
Introduction
The risk of adverse health effects in offspring due to maternal tobacco smoking during pregnancy is well
documented [1], including epigenetic changes persisting in the offspring after prenatal exposure [2]. The
effects of fetal exposure to nicotine from non-combustible tobacco products, such as snus or nicotine-
replacement therapies (NRTs), are less clear. Use of snus leads to systemic absorption of nicotine into the
maternal circulatory system, with subsequent exposure of the foetus through the placenta [3]. Recent
register studies suggest that compared to non-tobacco users snus use alone in pregnancy increases the risk
of stillbirth [4], preterm delivery [5] and small size for gestational age (GA) [6]. In addition, fetal nicotine
exposure in animal models has shown altered pulmonary development and health in offspring [7], as well
as epigenetic changes [8].
A substantial shift in the use of nicotine-containing products has recently been observed in many parts of
the world, particularly among the young. In the United States the overall use of any tobacco or nicotine
products reported by high school students in 2016 (20.2%) was similar to 5 years earlier, however, the use
of electronic cigarettes (e-cigarettes) increased from 1.5% to 11.3% while combustible tobacco use
decreased from 21.8% to 13.8% [9]. Similar shifts from smoking towards the use of other nicotine
products are observed in many Western countries [10–12], as shown by 29.9% of Polish youths reporting
the use of e-cigarettes in 2014 [11] and e-cigarettes being almost twice as common as smoking among
youths in Wales [12]. While e-cigarettes have been banned [13, 14] and infrequently used [15] in Norway
and Sweden, the shift from smoking has rather been towards snus which has been available for many
years. Snus, also termed moist snuff, is smokeless, ground tobacco placed between the gum and the lip [3].
Compared to cigarettes, snus gives a slower rise in nicotine plasma levels but a higher total concentration
over time [16]. In 2010, a 10-fold higher rate of snus use was reported in Sweden compared to other
European countries, where snus sales are limited [17]. From 2008 to 2017 the use of snus increased among
women in Norway, with daily snus use increasing from 5% to 14% among 16–24 year olds and from 1%
to 12% among 25–34 year olds [18].
The use of nicotine-containing products among young women is likely to be reflected in their use during
pregnancy, as seen with declining smoking rates in some countries which are also being reported during
pregnancy [19, 20]. Apart from register studies from Sweden [5], Norway [21] and the United States [22],
there is limited updated information on the use of other nicotine products (such as snus and NRTs) in
pregnancy. A recent study from Norway demonstrated a doubling of “daily” or “sometimes” snus use at
the start of pregnancy between 2012 and 2014, from 1.7% to 3.4%, with the highest rates among the 16–24
year olds [21].
In pregnancy, single women smokers with lower educational levels have the highest smoking prevalence
[23, 24] and the lowest smoking decline since 1999 [24]. While risk factors for snus use during pregnancy
are largely unknown, educational level has not in general been clearly associated with snus use [25, 26].
However, lower economic status [27], younger age, higher alcohol consumption, number of sexual partners
and heavy physical activity [26] have been.
Limited knowledge of the potential harmful effects of snus use in pregnancy, the alleged harm reduction
of snus use compared to smoking and animal studies suggesting that fetal exposure to nicotine is similar
in both snus and cigarette use, raise concerns about the continuing, albeit changing, patterns of nicotine
use by young women. The primary aim of the present study was therefore to determine the prevalence of
snus and other nicotine-containing product use during pregnancy. The secondary aim was to identify
factors associated with the use of snus.
Subjects and methods
Study design
The present study used data from the Preventing Atopic Dermatitis and ALLergies (PreventADALL) study [28],
a large population-based, prospective mother–child birth cohort. Briefly, between December 2014 and
October 2016, 2697 women with a total of 2701 pregnancies were recruited from general, nonselected
populations in Norway (2149 from Oslo University Hospital and Østfold Hospital Trust) and Sweden (552
from the Karolinska Institutet, Stockholm) at the routine ultrasound screening examination in gestational
week 18. Inclusion criteria were single and twin pregnancies at weeks 16–22 and sufficient Scandinavian
language skills. Exclusion criteria were severe maternal or fetal disease or the parents planning to move
away from the area within the baby’s first year of life. Healthy infants born at a GA of at least 35.0 weeks
were enrolled at birth, constituting 2397 mother–child pairs [28].
The enrolment visit included obtaining written informed consent, measures of height and weight, a brief
interview on the present and previous pregnancies, and information on how to complete the electronic
questionnaires at 18 and 34 weeks.
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The PreventADALL study was approved by the Regional Committee for Medical and Health Research
Ethics in South-Eastern Norway (2014/518) and in Sweden (2014/2242–31/4), and the study was registered
at ClinicalTrials.gov (number NCT02449850).
Subjects
The present study included all 2528 women who completed at least one of two electronic questionnaires.
The overall mean age among the 1985 women enrolled in Norway and the 543 women in Sweden was
32.4 years (range 20–48 years) as shown in table 1 and supplementary table S1.
Methods
The electronic questionnaires, developed in collaboration with the University Center for Information
Technology (USIT) at the University of Oslo [28], included detailed questions about all types of tobacco
TABLE 1 Background characteristics of the study population, comparing those women who
were included in the present analysis versus those who were not
Characteristics Inclusion in the present analysis
Yes# (n=2528) No# (n=173)
Maternal age years 32.4 (20–48)¶ 31.1 (18–44)¶
Maternal data
BMI before pregnancy (n=2460) 23.2 (13.8–45.7) 23.6 (17.1–44.1)
Height cm (n=2491) 168.0 (147.0–187.0) 167.4 (147.0–186.0)
Weight before pregnancy kg (n=2471) 65.4 (42.5–126.0) 64.2 (42.0–116.0)
Weight at inclusion kg (n=2498) 70.2 (44.8–132.7) 68.0 (45.8–117.0)
Previous pregnancy 1292 (51.1)
Previous pregnancies+ (n=2528)
0 1236 (48.9)
1 652 (25.8)
2 377 (14.9)
3 143 (5.7)
>3 120 (4.8)
Education (n=2350)
Preliminary school only (9–10 years) 18 (0.8)
High school only 239 (10.2)
Higher education <4 years 758 (32.2)
Higher education ⩾4 years 1324 (56.3)
Other 2 (0.1)
Unknown 9 (0.4)
Country of origin (n=2350)
Norway 1562 (66.5)
Sweden 523 (22.3)
Other nordic 31 (1.3)
Rest of the world 234 (10.0)
Marital status (n=2350)
Married 968 (41.2)
Cohabitant 1313 (55.9)
Single 44 (1.9)
Divorced/separated 1 (0.04)
Other 24 (1.0)
Living environment (n=2350)
City (densely populated) 916 (39.0)
City (less densely populated) 882 (37.5)
Suburb 373 (15.9)
Countryside (in village) 127 (5.4)
Countryside (outside village) 52 (2.2)
Data is presented as mean (min–max) or n (%). BMI: body mass index. #: subjects were included in the
present analysis if one or more questionnaires (from 18 weeks and 34 weeks) was completed. Subjects
were excluded if questionnaires were not completed. Total pregnancies at 18 weeks available for inclusion
was 2701. Total questionnaires completed at 18 weeks was 2350. ¶: p<0.001; +: number of reported
pregnancies excluding the current pregnancy.
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and nicotine use prior to and during pregnancy. The questionnaires were sent at a fixed time related to the
inclusion date (between the 16th and 22nd weeks of pregnancy), with an automatic reminder in case of no
response. The women specified their perceived week of pregnancy when completing the questionnaires.
The 18-week questionnaire included questions about ever use (daily or sometimes) of any tobacco or
nicotine product prior to and during pregnancy up to the time of completing the questionnaire, while the
34-week questionnaire asked about any use in the period since completing the previous questionnaire.
The questions regarding ever use of tobacco- or nicotine-containing products had separate detailed
follow-up questions for cigarette smoking and snus use, included the time of use (“stopped years before
pregnancy”, “stopped in the time before pregnancy”, “stopped when recognising pregnancy” or “current
use in pregnancy”), with further details of use in pregnancy or the week of pregnancy when stopping as
outlined in the supplementary material. There were no questions specifically determining if cessation was
in relation to antenatal visits.
Outcomes, definitions and explanatory variables
The main outcome was use of any nicotine-containing products such as snus, tobacco cigarettes, NRTs
and e-cigarettes during pregnancy. The main outcome was further reported for snus, smoking or dual
users reported as mutually exclusive categories, unless otherwise specified. Additional nicotine-containing
products included “e-cigarettes”, “cigars/cigarillos”, “pipes” or “other”, while NRTs were categorised as
“patches” or “gums/lozenges/sprays”.
To explore factors related to the use of snus in pregnancy, we included variables that have been associated
with smoking: country of origin, living environment, marital status, education level, total household
income, previous or current cigarette smoking, the index woman being exposed to maternal smoking in
utero, household cigarette smoking, age, pre-pregnancy body mass index (BMI), and number of previous
pregnancies (excluding current pregnancy) and deliveries.
Statistical analysis
Categorical variables are presented in numbers and percentages, and continuous variables as mean values
with maximum and minimum ranges. To address the rates of stopping use of nicotine-containing
products in pregnancy, we used data from all 2187 subjects who completed both questionnaires.
Differences between categorical variables were analysed by Chi-squared tests and numerical data by t-tests
or one-way ANOVA tests. Binary logistic regression was used to determine factors that might be associated
with the use of snus in pregnancy by first excluding potential covariates with a p-value greater than 0.25.
The significance level was set to 0.05 and all analyses were performed using IBM SPSS statistics version 25
(Chicago, IL, USA).
Results
Of the 2528 women who completed at least one questionnaire, 2350 completed the 18-week questionnaire,
2365 completed the 34-week questionnaire and 2187 completed both. The included women were similar to
those who did not complete any of the questionnaires, with the exception of a slightly higher age (table 1).
Background characteristics given by study location are described in supplementary table S1. The use of
nicotine-containing products prior to pregnancy is given in table 2, in the supplementary material and in
supplementary figure S1.
Prevalence
Based on the women who completed at least one of the 18- or 34-week questionnaires, any use of tobacco-
or nicotine-containing products at some time during pregnancy was reported by 286 out of 2528 subjects
(11.3%). Snus use alone was reported in 6.5% of cases, cigarette smoking alone in 4.1% of cases, dual use
in 0.6% of cases and use of NRTs/e-cigarettes in 0.2% of cases.
From the 18-week questionnaire, any use of tobacco- or nicotine-containing products until pregnancy
week 18 was reported by 284 out of 2350 of subjects overall (12.1%), with 12.5% reported in Norway and
10.7% reported in Sweden. Use of Snus alone was the most common form of nicotine-containing product
use, reported by 6.9% of subjects, while 4.3% reported smoking alone and 0.6% were dual users. Snus use
(including dual use) at some time during pregnancy was 7.6% in total and significantly more common in
Norway than in Sweden (8.2% versus 5.5%; p=0.035), as shown in table 2 and supplementary figure S1.
Current use of any nicotine-containing products at pregnancy week 18 was reported by 33 out of 2350
subjects (1.4%), with 0.6% using only snus and 0.8% being current smokers only. None reported current
dual use, as shown in table 2 and supplementary figure S1. Most current snus users were daily users of
three to six portions, a portion being a sealed pouch of snus (see the supplementary material for further
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details). The use of NRTs or e-cigarettes was uncommon until 18 weeks (0.2%), with two pregnant women
using nicotine gum and three using e-cigarettes. Of these women, four were previously cigarette smokers
or snus users.
Overall, 1.3% of the 2365 women completing the 34-week questionnaire reported use of any tobacco- and
nicotine-containing products in late pregnancy (defined as from 18 to 34 weeks). At pregnancy week 34,
0.3% were current snus users only and 0.3% were current cigarette smokers only (see table 2 and
supplementary figure S1). None of the women reported current use of NRTs and only one woman (0.04%)
reported use of e-cigarettes at some time between 18 and 34 weeks of pregnancy.
Based on reports from the 2187 women who completed both questionnaires, 245 out of 269 (91.1%) of the
women using snus (n=164) and/or cigarettes (n=105) at some time while pregnant stopped as soon as they
TABLE 2 Reported use of snus, cigarette smoke and nicotine-replacement therapies (NRTs)/
e-cigarettes in Norway and Sweden
Parameter Total Norway Sweden p-value#
Questionnaire adherence
Completed at 18 weeks 2350 (100.0) 1818 (77.4) 532 (22.6)
Completed 34 weeks 2365 (100.0) 1853 (78.4) 512 (21.7)
Completed one or more 2528 (100.0) 1985 (78.5) 543 (21.5)
Completed both 2187 (100.0) 1686 (77.1) 501 (22.9)
Tobacco habits
Ever use in life (n=2350)
All nicotine-containing products 840 (35.7) 680 (37.4) 160 (30.1) 0.002
Snus 529 (22.5) 434 (23.9) 95 (17.9) 0.003
Cigarette smoke 531 (22.6) 423 (23.3) 108 (20.3) 0.15
Use before pregnancy (n=2350)
Stopped years before pregnancy
Snus 213 (9.6) 165 (9.1) 48 (9.0) 0.97
Cigarette smoke 338 (14.4) 276 (15.2) 62 (11.7) 0.04
Stopped in the time before pregnancy
Snus 138 (5.9) 120 (6.6) 18 (3.4) 0.005
Cigarette smoke 77 (3.3) 65 (3.6) 12 (2.3) 0.13
Snus in pregnancy (including dual users)
At some time up to 18 weeks (n=2350) 178 (7.6) 149 (8.2) 29 (5.5) 0.035
Current use at 18 weeks 13 (0.6) 11 (0.6) 2 (0.4) 0.81
Stopped when recognising pregnancy 165 (7.0) 138 (7.6) 27 (5.1)
At some time from 18–34 weeks (n=2365) 18 (0.8) 14 (0.8) 4 (0.8) 0.95
Current use at 34 weeks 6 (0.3) 4 (0.2) 2 (0.4)
Stopped between 18 and 34 weeks 12 (0.5) 10 (0.5) 2 (0.4)
Cigarette smoke in pregnancy (including dual users)
At some time up to 18 weeks (n=2350) 116 (4.9) 82 (4.5) 34 (6.4) 0.08
Current use at 18 weeks 18 (0.8) 14 (0.8) 4 (0.8) 0.84
Stopped when recognising pregnancy 98 (4.2) 68 (3.7) 30 (5.6)
At some time from 18–34 weeks (n=2365) 14 (0.6) 10 (0.5) 4 (0.8) 0.53
Current use at 34 weeks 8 (0.3) 6 (0.3) 2 (0.4)
Stopped between 18 and 34 weeks 6 (0.3) 4 (0.2) 2 (0.4)
Dual snus and cigarette smoke in pregnancy
At some time up to 18 weeks (n=2350) 15 (0.6) 7 (0.4) 8 (1.5) 0.004
Current use at 18 weeks 0 0 0
Stopped when recognising pregnancy 15 (0.6) 7 (0.4) 8 (1.5)
At some time from 18–34 weeks (n=2365) 1 (0.04) 0 1 (0.2)
Current use at 34 weeks 0 0 0
Stopped between 18 and 34 weeks 1 (0.04) 0 1 (0.2)
NRTs/e-cigarettes in pregnancy
At some time up to 18 weeks (n=2350) 5 (0.2) 3 (0.2) 2 (0.4)
Current use at 18 weeks 2 (0.1) 1 (0.1) 1 (0.2)
Stopped when recognising pregnancy 3 (0.1) 2 (0.1) 1 (0.2)
At some time from 18–34 weeks (n=2365) 1 (0.1) 0 1 (0.2)
Current use at 34 weeks 1 (0.1) 0 1 (0.2)
Stopped between 18 and 34 weeks 0 0 0
#: p-values in bold (p<0.05) are significant.
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became aware of their pregnancy. As illustrated in figure 1 for snus and smoking, 143 out of 164 (87.2%)
quit snus and 83 out of 105 (79.1%) quit smoking by pregnancy week six. Only five women reported use
of NRTs or e-cigarettes until pregnancy week 18, of whom three reported quitting at recognised
pregnancy. Relapse was generally uncommon, with details given in the supplementary material.
Factors associated with use of snus in pregnancy
From our final multiple logistic regression analyses (Nagelkerke), we could explain 15% of snus use
(including dual cigarette smoking) in pregnancy based upon the significant predictors shown in figure 2.
The adjusted, significant predictors included inverse association with age, a positive association with urban
living (see supplementary figure S2 for details), cohabiting with the partner rather than being married (as
is common in Norway and Sweden), being native born in Norway or Sweden compared to elsewhere,
previous or current smoking history and the index women being exposed to smoking in utero. Maternal
education, household income, household smoking, pre-pregnancy BMI and the number of reported
previous pregnancies and deliveries were not significantly associated with the use of snus during
pregnancy.
Discussion
In this prospective mother–child birth cohort study from 2014, 11.3% of the women reported use of any
type of tobacco- or nicotine-containing product at some time during pregnancy up to 34 weeks. Use of
snus alone was most common (reported by 6.5% of women), followed by smoking only (4.1%), dual use
(0.6%) and NRTs or e-cigarettes (0.2%). However, most women stopped when recognising their
pregnancy, with 87.2% of snus users and 79.1% of smokers quitting by pregnancy week six. Snus use in
pregnancy was inversely associated with age and positively associated with urban living, being a cohabitant
compared to being married or a single mother, being native born in Norway or Sweden compared to other
countries, having a personal smoking history and being exposed to cigarettes in utero.
The 4.7% of women smoking during pregnancy (including 0.6% dual use) is much lower than rates in
similar birth cohort studies from Norway and Sweden around 25 years ago, with a 27% smoker rate in the
Environment and Childhood Asthma (ECA) study [29] and a 13% rate in the Swedish BAMSE study [30].
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FIGURE 1 Percentage of women using snus and/or cigarette smoke during pregnancy based on self-reported
time for stopping from those who completed both 18-week and 34-week questionnaires (n=2187). Time for
stopping categories were from 1–2 weeks to >16 weeks and from <17 weeks to 30–34 weeks, respectively.
Among the women who reported the use of snus, cigarette smoke or dual use at some time during
pregnancy, most stopped when they recognised their pregnancy (mean pregnancy week three to four). Week 0
reflects the total percentage of women who reported any use during pregnancy. E-cigarettes and nicotine
replacement therapies were not included since the rates were low.
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This favourable change harmonises with the decrease in overall smoking rates among pregnant women
and the population in general, a trend seen in some [19, 20] but not all [31, 32] countries in the past
decades. In contrast, snus use in pregnancy has been largely unknown until recently. The 7.6% of women
using snus at some time until week 18 of pregnancy (including 0.6% dual use) is somewhat higher than
recent registry studies from Norway [21] and Sweden [33]. The 8.2% of pregnant Norwegian women
reporting snus use in our study (including 0.4% dual use) is substantially higher than the 3.4% of first
trimester snus use recorded in 2014 that was obtained from a hospital register in Southern Norway [21].
Likewise, the 5.5% of snus use during pregnancy in the Swedish part of our study (including 1.5% dual
use) exceeded the 1.2% of snus use in early pregnancy reported in the Swedish Birth Register in 2016 [33].
However, the rate of snus use alone in late pregnancy (0.3%) was similar to the Norwegian and Swedish
registries [21, 33]. The higher rates among pregnant women reported in our study, with data recorded
from 2014 to 2016, probably reflect the recent rapid increase in snus use among young women [27]. The
low prevalence of NRT and e-cigarette use in the present study is, to the best of our knowledge, not
previously reported. It should also be noted that we collected data only on tobacco and nicotine products
available in Scandinavia and thus products such as “hookah” are not reported.
That the majority of women stopped using snus or stopped smoking by week six of pregnancy is good
news and has to our knowledge not been reported previously. It is in line with the reported drop in the
prevalence of snus use from early to late pregnancy in the Swedish and Norwegian birth registries [21, 33].
A growing body of evidence demonstrates that the beginning of life, including the time before conception,
during pregnancy and in infancy, is a critical period in setting the trajectory towards an increased risk of
non-communicable diseases [34]. As epigenetic changes are likely to impact developmental programming
in the context of Developmental Origins of Health and Disease (DOHaD) [35], avoiding nicotine overall,
even before recognising pregnancy, is important. In this study, the early “stopping when knowing” that is
likely to occur even before the first antenatal visit suggests an active choice to abstain from potentially
harmful exposure to the unborn child.
The inverse association of snus use with age, the positive association with urban living and lack of
association with educational attainment in our study differ from the lower educational level seen among
smokers [36]. However, our predictors for snus use appear more similar to non-daily smokers than daily
smokers in terms of educational level, income, marital status, weight and the rate of spontaneously
quitting in early pregnancy [37]. The explained variation in predictors of snus use in pregnancy was only
15%, but was quite similar to predictors of smoking in pregnancy [38]. In this study, previous smoking
history and exposure to maternal prenatal smoking were factors associated with using snus in pregnancy.
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FIGURE 2 Factors associated with snus use during pregnancy. In multivariate analysis, the following factors
were identified as associated with the use of snus at some time during pregnancy (reference categories are
presented in italic for each factor): living area (countryside (village) versus city (densely populated), city (less
densely populated), suburb, countryside (outside village)); grand maternal cigarette smoking (no versus yes,
do not know); country of origin (rest of the world and other nordic countries combined versus Norway or
Sweden); previous and/or current smoking (no versus yes); marital status (married versus cohabitant, single,
divorced/separated, other). Age was used as a continuous variable. OR: odds ratio. #: in utero smoking
exposure of the index woman; *: p<0.05; **: p<0.01.
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This corresponds with a study demonstrating an intergenerational association of mothers’ and daughters’
smoking habits during pregnancy, indicating that daughters exposed in utero were more likely to smoke
when pregnant than unexposed daughters [39]. Though the mechanism behind this is multifactorial and
likely includes behavioural, (epi)genetic and environmental factors [39], it suggests a nicotine susceptibility
affecting the risk of use in pregnancy.
The present study is strengthened by its prospective design, with a high follow-up rate where detailed
information on tobacco and nicotine use is reported twice during pregnancy. The higher educational
attainment level in our study compared to society at large [28] is unlikely to impact the observed
prevalence rates, as maternal education was not associated with snus use and our findings largely reflect
the rapidly changing societal use of snus. The under-reporting of the use of tobacco products cannot be
excluded in this questionnaire-based study, nor did we have biological assays to confirm nicotine exposure.
However, self-reported data may be sufficiently accurate as a high degree of association between
self-reported tobacco use and nicotine exposure, as assessed by blood cotinine drawn at delivery, has
been found [40]. Our data showed a higher prevalence than previously reported from a national health
register [21], suggesting that under-reporting may be limited in this prospective study.
Conclusion
In the present study, the 11.3% use of tobacco- and nicotine-containing products during pregnancy was
lower than two decades ago, but the prevalence of snus use alone (6.5%) was higher than in recent registry
reports. Of snus users, 87.2% quit by week six of pregnancy. Snus use in pregnancy was inversely
associated with age and was more common among urban living, cohabitating women with a personal or
maternal history of smoking.
In order to give appropriate advice to pregnant women there is an urgent need for large prospective
studies investigating potential harmful effects on offspring following the use of non-combustible nicotine
products in pregnancy. In the meanwhile, the precautionary principle should be advocated for all types of
tobacco and nicotine products in pregnancy.
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